Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P56539

UPID:
CAV3_HUMAN

ALTERNATIVE NAMES:
M-caveolin

ALTERNATIVE UPACC:
P56539; A8K777; Q3T1A4

BACKGROUND:
Caveolin-3, identified by its alternative name M-caveolin, serves as a critical component in caveolar membranes, regulating G-protein alpha subunits and voltage-gated potassium channels. Its role extends to the repair of the sarcolemma in muscle cells, indicating its importance in cellular integrity and signaling.

THERAPEUTIC SIGNIFICANCE:
The association of Caveolin-3 with various diseases, including HyperCKmia, Rippling muscle disease 2, familial hypertrophic cardiomyopathy, Long QT syndrome 9, and Sudden infant death syndrome, highlights its significance in medical research. Exploring Caveolin-3's functions could lead to innovative treatments for these diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.